Rocket Pharmaceuticals (RCKT) Prepaid Assets (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Prepaid Assets of $5.4 million for Q1 2026, up 43.18% sequentially from $3.8 million in Q4 2025, and down 13.92% YoY from $6.3 million in Q1 2025.
Analysis
Rocket Pharmaceuticals (RCKT) Prepaid Assets (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Prepaid Assets for 13 years, with the latest figure at $5.4 million in Q1 2026.
- Quarterly Prepaid Assets fell 13.92% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 13.92% YoY) and the FY2025 annual result came in at $3.8 million, down 34.92% from the prior year.
- Prepaid Assets improved to $5.4 million in Q1 2026 per RCKT's latest filing, from $3.8 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $14.8 million in Q1 2024 and troughed at $3.8 million in Q4 2025.
- A 5-year average of $6.9 million and a median of $5.8 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets surged 176.12% in 2024, then tumbled 59.27% in 2025.
- Over 5 years, Prepaid Assets stood at $7.7 million in 2022, then sank by 34.16% to $5.0 million in 2023, then grew by 15.85% to $5.8 million in 2024, then plunged by 34.92% to $3.8 million in 2025, then soared by 43.18% to $5.4 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $5.4 million, $3.8 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.80 Mn |
| Mar 31, 2026 | 5.45 Mn |
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 4.92 Mn |
| Jun 30, 2025 | 5.66 Mn |
| Mar 31, 2025 | 6.33 Mn |
| Dec 31, 2024 | 5.85 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 13.90 Mn |
| Mar 31, 2024 | 14.85 Mn |
| Dec 31, 2023 | 5.05 Mn |
| Sep 30, 2023 | 9.69 Mn |
| Jun 30, 2023 | 5.03 Mn |
| Mar 31, 2023 | 6.95 Mn |
| Dec 31, 2022 | 7.67 Mn |
| Sep 30, 2022 | 4.60 Mn |
| Jun 30, 2022 | 4.40 Mn |
| Mar 31, 2022 | 7.26 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Sep 30, 2021 | 3.61 Mn |